Publikationen 2024

Morath O, Crodel C, Rinke J, Sander I, Tekbas A, Meggendorfer M, Baer C, Hochhaus A, Ernst T. Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients. Hamostaseologie. 2024 Dec 21. doi: 10.1055/a-2410-8530. Epub ahead of print. PMID: 39708833

Gale RP, Hochhaus A. Mpox in people with haematological cancers. Leukemia. 2024 Dec 13. doi: 10.1038/s41375-024-02465-7. Epub ahead of print. PMID: 39672828

Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Epub ahead of print. PMID: 39661985

Ernst T, Fall 1: 70-Jährige mit mehrfacher TKI-Intoleranz und kardiovaskulären Begleiterkrankungen. Thieme Case Report, Chronische myeloische Leukämie, August 2024; 1-12

Hochhaus A, Asciminib bewährt sich auch im Langzeitverlauf als effektive und verträgliche Therapie. Thieme Case Report, Chronische myeloische Leukämie, August 2024; 1-12

Salomo S, Hübner J. Development and implementation of a new part-time continuing education course in integrative oncology. GMS J Med Educ. 2024;41(5):Doc64. DOI: 10.3205/zma001719, URN: urn:nbn:de:0183-zma0017190

Hübner J., Wölfl, H., Otto, L. et al. Patienteninitiierte Forschung in der Onkologie. Onkologie (2024). https://doi.org/10.1007/s00761-024-01622-y

Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia. Blood Adv. 2024 Nov 6:bloodadvances.2024013304. doi: 10.1182/bloodadvances.2024013304. Epub ahead of print. PMID: 39504561

Saur FG, Keinki C, Cramer A, Buentzel J, Hübner J. Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs. Clin Exp Dent Res. 2024 Dec;10(6):e70024. doi: 10.1002/cre2.70024. PMID: 39497340

Fleischmann M, Jentzsch M, Brioli A, Eisele F, Frietsch JJ, Eigendorff F, Tober R, Schrenk KG, Hammersen JF, Yomade O, Hilgendorf I, Hochhaus A, Scholl S, Schnetzke U. Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Ann Hematol. 2024 Oct 25. doi: 10.1007/s00277-024-06048-5. Epub ahead of print. PMID: 39453477

Wickel J, Schnetzke U, Sayer-Klink A, Rinke J, Borie D, Dudziak D, Hochhaus A, Heger L, Geis C. Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med. 2024 Oct 17:101794. doi: 10.1016/j.xcrm.2024.101794. Epub ahead of print. PMID: 39447569

Elnahas M, Hübner J, Lang PM, Ahmadi E. Job Satisfaction Among First-Generation Migrant Physicians in Anesthesiology and Intensive Care Medicine in Germany. Healthcare. 2024; 12(21):2107. https://doi.org/10.3390/healthcare12212107

Gutsche LC, Dörfler J, Hübner J. Curcumin as a complementary treatment in oncological therapy: a systematic review. Eur J Clin Pharmacol. 2024 Oct 19. doi: 10.1007/s00228-024-03764-9. Epub ahead of print. PMID: 39425780

Krannich F, Mücke R, Büntzel J, Schomburg L, Micke O, Huebner J, Dörfler J. A systematic review of Selenium as a complementary treatment in cancer patients. Complement Ther Med. 2024 Oct 5:103095. doi: 10.1016/j.ctim.2024.103095. Epub ahead of print. PMID: 39374898

Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kröger N, Ayuk FA, Stoelzel F, Middeke JM, Eder M, Bethge W, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante M, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau IW, Burchert A, Wulf G, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhaeuser M, Schmeller S, Schetelig J. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study). Blood. 2024 Oct 3;144(14):1532-1542. doi: 10.1182/blood.2024024342. PMID: 39007722

Hochhaus, A., Geissler, J. Patientenbeteiligung im CML-Studiennetzwerk. Onkologie (2024). https://doi.org/10.1007/s00761-024-01598-9

Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.283428. Epub ahead of print. PMID: 38695123

Davitian K, Noack P, Eckstein K, Hübner J, Ahmadi E. Barriers of Ukrainian refugees and migrants in accessing German healthcare. BMC Health Serv Res. 2024 Sep 24;24(1):1112. doi: 10.1186/s12913-024-11592-x. PMID: 39317924

Stege H, Schneider S, Forschner A, Eigentler T, Nashan D, Huening S, Lehr S, Meiss F, Kaatz M, Kuchen R, Kaehler KC, Haist M, Grabbe S, Huebner J, Loquai C. Second opinion and self-efficacy in German skin cancer patients. J Dtsch Dermatol Ges. 2024 Sep 12. doi: 10.1111/ddg.15512. Epub ahead of print. PMID: 39263772

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. PMID: 38971175

Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. JCO 43, 65-74(2025).DOI:10.1200/JCO.24.00235

Dörfler, J., Hübner, J. Neuerungen in der aktualisierten S3-Leitlinie „Komplementärmedizin in der Behandlung von onkologischen PatientInnen“. Forum (2024). https://doi.org/10.1007/s12312-024-01367-0

Ernst P, Rinke J, Franke GN, Dicker F, Haferlach T, Ernst T, Hochhaus A. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation. Leukemia. 2024 Sep;38(9):2037-2040. doi: 10.1038/s41375-024-02327-2. Epub 2024 Jul 4. PMID: 38965368; PMCID: PMC11347363

Klaus M, Kutschan S, Männle H, Hübner J, Dörfler J. Reflexology in oncological treatment - a systematic review. BMC Complement Med Ther. 2024 Jan 11;24(1):32. doi: 10.1186/s12906-023-04220-4. PMID: 38212747; PMCID: PMC10782728

Chronic myeloid leukemia. Second edition. Editor-en-chief (Germany) Rüdiger Hehlmann, translated by Li Weiming, Beijing: Academic Literature Press, 2024.3, ISBN 978-7-5235-1167-1, first published in English under the title Chronic Myeloid Leukemia (2nd Ed.), edited by Rüdiger Hehlmann, Copyright Rüdiger Hehlmann, 2021. This edition has been translated an published under licence from Springer Nature Switzerland AG. Matthew Salmon, Helen E. White, Nocholas C.P. Cross, and Andreas Hochhaus: 2021 update: Standardization of molecular surveillance in chronic myeloid leukemia

Gambacorti-Passerini C, Brümmendorf TH, Abruzzese E, Kelly KR, Oehler VG, García-Gutiérrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles FJ, Hochhaus A. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372-x. Epub ahead of print. PMID: 39164407

Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L, Vol. 109 No. 8 (2024): August, 2024, https://haematologica.org/article/view/haematol.2024.285225

Dörfler J, Freuding M, Zaiser C, Büntzel J, Keinki C, Käsmann L, Hübner J. Umbrella review: Summary of findings for acupuncture as treatment for radiation-induced xerostomia. Head Neck. 2023 Apr;45(4):1026-1044. doi: 10.1002/hed.27297. Epub 2023 Feb 13. PMID: 36779370

Viktoria Mathies, Oliver Krings, Christian Keinki, Oliver Micke, and Jutta Hübner.Vitamin D deficiency in cancer care: Information, diagnosis, and supplementation from the patients’ point of view . 2023; 40: 143-151. doi: 10.5414/TE500060.

Hübner J, Keinki C, Münstedt K. Alternativmedizin in der Uroonkologie [Alternative medicine in uro-oncology]. Urologie. 2023 Jan;62(1):34-40. German. doi: 10.1007/s00120-022-01990-6. Epub 2022 Dec 1. PMID: 36454273

Cramer A., Keinki, C., Saur, F. et al. eHealth literacy, internet and eHealth service usage: a survey among a German municipality. J Public Health (Berl.) (2023). https://doi.org/10.1007/s10389-023-01997-z

Brandt F, Schneider N, Altmann U, Strauß B, Hübner J, Keinki C. Psychometrische Eigenschaften des Qualiskope-A zur Messung der Patientenzufriedenheit mit der ambulant-ärztlichen Behandlung: Einsatz in der Onkologie und Übertragbarkeit auf die stationäre Versorgung [Psychometric Properties of the Qualiskope-A for Measuring Patient Satisfaction with Outpatient Medical Treatment: Use in Oncology and Transferability to Inpatient Care]. Gesundheitswesen. 2023 Aug;85(8-09):732-740. German. doi: 10.1055/a-2016-7948. Epub 2023 Apr 7. PMID: 37028417; PMCID: PMC11248893

Schütt J, Brinkert K, Plis A, Schenk T, Brioli A. Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review. Cancer Drug Resist. 2024 Jun 26;7:26. doi: 10.20517/cdr.2024.39. PMID: 39050883; PMCID: PMC11267153

Haematolymphoid Tumours. WHO Classification of Tumours, 5th Edition, Volume 11; 2024; ISBN-13 978-92-832-4520-9; IARC Publications Website - Haematolymphoid Tumours (who.int)

Schneider N, Altmann U, Brandt F, Hübner J, Strauss B, Keinki C. A web-based knowledge database to provide evidence-based information to cancer patients: Utilization within the PIKKO study. Support Care Cancer. 2024 Jul 17;32(8):521. doi: 10.1007/s00520-024-08725-7. PMID: 39017937; PMCID: PMC1125498

Zibrova D, Ernst T, Hochhaus A, Heller R. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling. Mol Cell Biochem. 2024 Jul 15. doi: 10.1007/s11010-024-05070-5. Epub ahead of print. PMID: 39009935

Ma Y, Nenkov M, Berndt A, Abubrig M, Schmidt M, Sandhaus T, Huber O, Clement JH, Lang SM, Chen Y, Gaßler N. The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer. Cancers (Basel). 2024 Mar 16;16(6):1170. doi: 10.3390/cancers16061170. PMID: 38539505; PMCID: PMC10969076

Schnetzke U, Fischer M, Röllig C, Scherag A, Altmann H, Stölzel F, Alakel N, Bornhäuser M, Hochhaus A, Scholl S. Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy. Genes Immun. 2024 Jul 9. doi: 10.1038/s41435-024-00285-4. Epub ahead of print. PMID: 38982248

Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341-4. Epub ahead of print. PMID: 38987274

Morath O, Hoffmann J, Schilling K, Hochhaus A, Rachow T, Lang SM. Venous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis. Journal of Clinical Medicine. 2024; 13(13):3773. https://doi.org/10.3390/jcm13133773

Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol. 2024 Jul 5. doi: 10.1007/s00277-024-05867-w. Epub ahead of print. PMID: 38967662

von Grundherr J, Elmers S, Koch B, Hail LA, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann FT, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen CF, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer AK, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J. A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study. JAMA Netw Open. 2024 Mar 4;7(3):e242375. doi: 10.1001/jamanetworkopen.2024.2375. PMID: 38526495; PMCID: PMC10964114

Ernst P, Rinke J, Franke GN. et al. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation. Leukemia (2024). https://doi.org/10.1038/s41375-024-02327-2

Gale RP, Jiang Q, Apperley JF, Hochhaus A. Is there really an accelerated phase of chronic myeloid leukaemia? Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02316-5. Epub ahead of print. PMID: 38918562

Oliinyk D, Will A, Schneidmadel FR, Böhme M, Rinke J, Hochhaus A, Ernst T, Hahn N, Geis C, Lubeck M, Raether O, Humphrey SJ, Meier F. µPhos: a scalable and sensitive platform for high-dimensional phosphoproteomics. Mol Syst Biol. 2024 Jun 21. doi: 10.1038/s44320-024-00050-9. Epub ahead of print. PMID: 38907068

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, Suchankova P, Burda P, Hochhaus A, Machova Polakova K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13. PMID: 38615117; PMCID: PMC11147753

Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. PMID: 38820078

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators; Investigators. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024 Jun 1;42(16):1875-1880. doi: 10.1200/JCO.23.01647. Epub 2024 Mar 12. PMID: 38471049

Ritschel ML, Hübner J, Wurm-Kuczera R, Büntzel J. Phytotherapy known and applied by head-neck cancer patients and medical students to treat oral discomfort in Germany: an observational study. J Cancer Res Clin Oncol. 2023 May;149(5):2057-2070. doi: 10.1007/s00432-022-04200-0. Epub 2022 Jul 23. PMID: 35870011; PMCID: PMC10097744

Therapie-Handbuch Onkologie und Hämatologie. Praxishandbuch. Hubert Serve, David Zurmeyer (Herausgeber). Komplementärmedizin (Hübner J) Buch | Softcover. XXII, 504 Seiten. 2024 | 2., erweiterte und aktualisierte Auflage. Urban & Fischer in Elsevier (Verlag). 978-3-437-21011-2 (ISBN)

Beksac M, Eikema DJ, Koster L, Hulin C, Poiré X, Hamladji RM, Gromek T, Bazarbachi A, Ozkurt ZN, Pabst T, Ben Othman T, Finke J, Pirogova O, Wu D, Hayat A, Hilgendorf I, Tholouli E, de Wreede LC, Schönland S, Garderet L, Drozd-Sokolowska J, Raj K, Hayden PJ, Yakoub-Agha I, McLornan DP. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024 Apr;59(4):526-533. doi: 10.1038/s41409-023-02160-8. Epub 2024 Jan 31. PMID: 38297040; PMCID: PMC10994834

Schulz F, Jäger P, Tischer J, Fraccaroli A, Bug G, Hausmann A, Baermann BN, Tressin P, Hoelscher A, Kasprzak A, Nachtkamp K, Schetelig J, Hilgendorf I, Germing U, Dietrich S, Kobbe G. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers (Basel). 2024 Jan 26;16(3):532. doi: 10.3390/cancers16030532. PMID: 38339283; PMCID: PMC10854830

Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278-8. Epub ahead of print. PMID: 38755421

Eigendorff F, Filimonova I, Scholl S, Sayer-Klink A, Rummler S, Kunert C, Pietschmann K, Wittig A, Hochhaus A, Schnetzke U. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study. J Cancer Res Clin Oncol. 2024 May 1;150(5):224. doi: 10.1007/s00432-024-05765-8. PMID: 38693452; PMCID: PMC11062962

Hofinger J, Kaesmann L, Buentzel J, Scharpenberg M, Huebner J. Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival. J Cancer Res Clin Oncol. 2024 Apr 29;150(4):219. doi: 10.1007/s00432-024-05742-1. PMID: 38679615; PMCID: PMC11056339

Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L. Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Epub ahead of print. PMID: 38654660

Masetti M, Al-Batran SE, Goetze TO, Thuss-Patience P, Knorrenschild JR, Goekkurt E, Folprecht G, Ettrich TJ, Lindig U, Luley KB, Pink D, Dechow T, Sookthai D, Junge S, Loose M, Pauligk C, Lorenzen S. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. Int J Cancer. 2024 Jun 15;154(12):2142-2150. doi: 10.1002/ijc.34894. Epub 2024 Mar 6. PMID: 38447003

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, Suchankova P, Burda P, Hochhaus A, Machova Polakova K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248-0. Epub ahead of print. PMID: 38615117

Eichenauer DA, Heger JM, Kruschel I, Kutsch N, Gödel P, Garcia Borrega J, Schnetzke U, Böll B, Neumann MA, Gebel C, Pralong A, Borchmann P, Voltz R, Wedding U, Simon ST. Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy. Br J Haematol. 2024 Mar 24. doi: 10.1111/bjh.19434. Epub ahead of print. PMID: 38522848

Hübner J: Komplementäre Onkologie. Verlag: Urban & Fischer in Elsevier, ISBN: ISBN 978-3-437-15076-0; eISBN 978-3-437-05413-6

Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204-y. Epub ahead of print. PMID: 38548962

Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229-3. Epub ahead of print. PMID: 38531949

Fleischmann M, Bechwar J, Voigtländer D, Fischer M, Schnetzke U, Hochhaus A, Scholl S. Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation. Cancers. 2024; 16(7):1311. https://doi.org/10.3390/cancers16071311

Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. Am J Hematol. 2024 Apr;99(4):759-762. doi: 10.1002/ajh.27232. Epub 2024 Feb 5. PMID: 38314531

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647. Epub ahead of print. PMID: 38471049

Smith BD, Brümmendorf TH, Roboz GJ, Gambacorti-Passerini C, Charbonnier A, Viqueira A, Leip E, Purcell S, Goldman EH, Giles F, Ernst T, Hochhaus A, Rosti G. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leuk Res. 2024 Apr;139:107481. doi: 10.1016/j.leukres.2024.107481. Epub 2024 Mar 11. PMID: 38484432

Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk FA, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf TH, Hofmann WK, Klein S, Jost E, Reiter A, Panse J. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries. Leukemia. 2024 Apr;38(4):810-821. doi: 10.1038/s41375-024-02186-x. Epub 2024 Mar 6. PMID: 38448757; PMCID: PMC10997505

Hochhaus A, Hörst K, Kühn C, Kvasnicka HM, Reiter A: Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5. Medizinische Genetik, vol. 36, no. 1, 2024, pp. 31-38. https://doi.org/10.1515/medgen-2024-2003

Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232. Epub ahead of print. PMID: 38314531

Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159-0. Epub ahead of print. PMID: 38287132

Zeidler J, Kutschan S, Dörfler J, Büntzel J, Huebner J. Impact of nutrition counseling on nutrition status in patients with head and neck cancer undergoing radio- or radiochemotherapy: a systematic review. Eur Arch Otorhinolaryngol. 2024 Jan 4. doi: 10.1007/s00405-023-08375-1. Epub ahead of print. PMID: 38175263

Knauft J, Schenk T, Ernst T, Schnetzke U, Hochhaus A, La Rosée P, Birndt S. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia. 2024 Jan 18. doi: 10.1038/s41375-024-02135-8. Epub ahead of print. PMID: 38238443